Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

Cancer

Volumn 118, Issue 21, 2012, Pages 5358-5365

  Qi, Yingwei ^a   Allen Ziegler, Katie L ^a   Hillman, Shauna L ^a   Redman, Mary W ^b   Schild, Steven E ^c   Gandara, David R ^d   Adjei, Alex A ^e   Mandrekars, Sumithra J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

advanced lung cancer; clinical trials; disease progression date; progression free survival; tumor assessment schedule

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DETERIORATION; DISEASE DURATION; DISEASE PROGRESSION DATE DETERMINATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIMULATION; SURVIVAL TIME; THORAX RADIOGRAPHY;

CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867864337     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27528     Document Type: Article

References (40)

1. Mandrekar SJ, Qi Y, Hillman SL, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 3-9.
2. Buyse M, Squifflet P, Laporte S, et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials [abstract]. J Clin Oncol. 2008; 26 (May 20 suppl). Abstract 8019.
3. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008; 26: 463-467.
4. Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011; 117: 1262-1271.
5. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst. 1999; 91: 1281-1287.
6. Wilkerson J, Fojo T,. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 2009; 15: 379-385.
7. Tuma R,. Progression-free survival remains debatable endpoint in cancer trials. J Natl Cancer Inst. 2009; 101: 1439-1441.
8. Broglio KR, Berry DA,. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101: 1642-1649.
9. Freidlin B, Korn EL, Hunsberger S, et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007; 25: 2122-2126.
10. Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007; 99: 428-432.
11. Bhattacharya S, Fyfe G, Gray RJ, et al. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009; 27: 5958-5964.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
13. Eisenhauer EA, Therasse P, Bogaert J, et al. New Response Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
14. Kanard A, Jatoi A, Castillo R, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer. 2004; 43: 345-353.
15. Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol. 2010; 5: 1346-1353.
16. Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of 3 schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5929-5937.
17. Mc Kean H, Stella PJ, Hillman SL, et al. Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group study N0222. Cancer Invest. 2011; 29: 266-271.
18. Jatoi A, Hillman SL, Ziegler KL, et al. Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group studies N9921 and N0222. Cancer Manag Res. 2009; 1: 61-68.
19. Dy GK, Hillman SL, Rowland KM Jr, et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 2010; 116: 5686-5693.
20. Adjei AA, Mandrekar SJ, Dy GK, et al. A phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer (NSCLC): an NCCTG and SWOG study. J Clin Oncol. 2010; 28: 614-619.
21. Chee CE, Jett JR, Bernath AM Jr, et al. Phase II trial of pemetrexed disodium and carboplatin in previously untreated extensive stage small cell lung cancer, N0423. Cancer. 2010; 116: 2382-2389.
22. Bryce AH, Mattar B, Hillman SL, et al. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: a North Central Cancer Treatment Group Study. Am J Clin Oncol. 2010; 33: 353-357.
23. Molina JR, Mandrekar SJ, Rowland KM, et al. A phase II NCCTG "window of opportunity" front-line study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC [abstract]. J Thorac Oncol. 2007; 2 (8 suppl): S413.
24. Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2010; 28 (15 suppl). Abstract 7603.
25. Molina JR, Foster NR, Nelson GD, et al. A phase II trial of the c-Src inhibitor AZD-0530 after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer (ES-SCLC). Paper presented at: 13th World Conference on Lung Cancer; July 31 to August 4, 2009; San Francisco, Calif.
26. Molina JR, Dy GK, Foster NR, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 7513.
27. Hesketh PJ, Chansky K, Lau DH, et al. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006; 1: 537-544.
28. Davies AM, Chansky K, Lara PN Jr, et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009; 4: 87-92.
29. Hesketh PJ, Chansky K, Wozniak AJ, et al. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008; 3: 1026-1031.
30. Herbst RS, Kelly K, Chansky K, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010; 28: 4747-4754.
31. Akerley W, McCoy J, Hesketh PJ, et al. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007; 2: 526-530.
32. Lara PN Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006; 1: 996-1001.
33. Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010; 5: 1835-1840.
34. Wellner JA, Zhan Y,. A hybrid algorithm for computation of the nonparametric maximum likelihood estimator from censored data. J Am Stat Assoc. 1997; 92: 945-959.
35. Zhao Q, Sun J,. Generalized log-rank test for mixed interval-censored failure time data. Stat Med. 2004; 23: 1621-1629.
36. So Y, Johnston G, Kim SH,. Analyzing Interval-Censored Survival Data With SAS Software. Cary, NC: SAS Institute and the University of North Carolina-Chapel Hill; 2010. Macros available at: http://support.sas.com/kb/ 24980.html. Accessed January 28, 2011.
37. The R Project for Statistical Computing. R interval censoring package-Icens. Available at: http://cran.r-project.org/web/packages/Icens/index. html. Accessed May 10, 2011.
38. US Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics, 2007 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071590.pdf. Accessed March 20, 2011.
39. Amit O, Bushnell W, Dodd L, Roach N, et al. Blinded independent central review of the progression-free survival endpoint. Oncologist. 2010; 15: 492-495.
40. Fridlyand J, Kaiser LD, Fyfe G,. Analysis of tumor burden versus progression-free survival for Phase II decision making. Contemp Clin Trials. 2011; 32: 446-452.